AI Assistant
Blog
Pricing
Log In
Sign Up
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study
Details
Cite
Export
Add to List
This content is not available in your region!
Continue researching
here.
